GlassScriptPhysician profile
Rocio Labrada
NPI 1154923290
$3,225.90
in general payments reported to CMS, 2019-2025
20 companies · $659 in 2025
The $659 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $389 · 2022: $733 · 2023: $291 · 2024: $1,153 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $822.43 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $543.02 | 2022-2025 | |
| Novo Nordisk INC | $534.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $276.71 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.50 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $112.88 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $106.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $105.13 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $100.10 | 2022 | |
| Phadia US INC. | $94.03 | 2023-2025 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $82.45 | 2022-2024 | |
| Amgen INC. | $76.89 | 2023-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $56.63 | 2022 | |
| Sumitomo Pharma America, INC. | $51.90 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $47.55 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $22.89 | 2025 | |
| Abbott Laboratories | $21.62 | 2021 | |
| Esperion Therapeutics, INC. | $19.69 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.87 | 2024 | Trulance, Xifaxan |
| Biohaven Pharmaceuticals, INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocio Labrada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.